Granted Patent
B2
US 12,544,333 · App. 18/431,490 · Granted Feb 10, 2026
Lipid vesicle compositions with penetration enhancing agents
Assignee:
DDS RESEARCH INC.
A61K9/127A61K8/14A61K9/0014A61K9/1273A61K47/10A61K47/14A61K47/186A61K47/22A61K47/24A61P17/00A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.
Claims (20)
1 . A method of delivering a compound to a skin of a subject, the method comprising applying to the skin of the subject an effective amount of one or more biphasic lipid vesicles, wherein a biphasic lipid vesicle of the one or more biphasic lipid vesicles comprises: (i) the compound; and (ii) one or more penetration enhancing agents comprising one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, wherein the one or more non-ionic surfactants having a HLB of about 10 or less comprises diethylene glycol monooleyl ether, sorbitan monopalmitate, or polyoxy ethylene (4) dilaurate.
2 . The method of claim 1 , wherein the compound is hydrophobic.
3 . The method of claim 1 , wherein the compound is hydrophilic.
4 . The method of claim 1 , wherein the compound comprises a small molecule, peptide, carbohydrate, or nucleic acid.
5 . The method of claim 1 , wherein the one or more biphasic lipid vesicles are formulated for topical delivery of the compound.
6 . The method of claim 5 , wherein the topical delivery comprises delivery to a skin or a mucosal membrane of the subject in need thereof.
7 . The method of claim 5 , wherein the topical delivery comprises intradermal delivery, transdermal delivery, or transmucosal delivery.
8 . The method of claim 1 , wherein the one or more biphasic lipid vesicles are applied daily, weekly, or monthly to the skin of the subject.
9 . The method of claim 1 , wherein the one or more biphasic lipid vesicles are applied for a duration sufficient to alleviate a skin condition.
10 . The method of claim 9 , wherein the skin condition is related to excessive or defective collagen production.
11 . The method of claim 10 , wherein the skin condition related to excessive or defective collagen production comprises skin aging, skin elasticity, striae, stretchmarks, wrinkles, a collagen vascular disease or a hereditary collagen disease, wherein the collagen vascular disease comprises cutaneous scleroderma, morphoea, lupus, rheumatoid arthritis, or temporal arteritis, and wherein the hereditary collagen disease comprises Ehlers-Danlos syndrome or Marfan's syndrome.
12 . The method of claim 1 , wherein the effective amount is based in part on one or more of: a pharmacodynamic property of the compound, a mode of administration, age, health, or weight of the subject, extent of a skin condition, frequency of application, type of concurrent treatment, or clearance rate of the compound in the subject.
13 . The method of claim 1 , wherein the one or more penetration enhancing agents increases a quantity of the compound absorbed into a quantity of skin by at least 10% relative to an otherwise same composition without the one or more penetration enhancing agents.
14 . The method of claim 1 , wherein the one or more biphasic lipid vesicles further comprise a lipid bilayer comprising vesicle forming lipids.
15 . The method of claim 14 , wherein the one or more biphasic lipid vesicles further comprise an oil-in-water emulsion entrapped in the lipid bilayer.
16 . The method of claim 15 , wherein the one or more penetration enhancing agents is entrapped in the lipid bilayer or the oil-in-water emulsion.
17 . The method of claim 16 , wherein the lipid bilayer comprises 0.1 wt % to 20 wt % of the one or more penetration enhancing agents.
18 . The method of claim 16 , wherein the oil-in-water emulsion comprises 0.01 wt % to 20 wt % of the one or more penetration enhancing agents.
19 . The method of claim 15 , wherein the oil-in-water emulsion comprises an aqueous continuous phase and a dispersed oil phase, and wherein the dispersed oil phase comprises droplets having an average diameter of less than 1 μm.
20 . The method of claim 15 , wherein the oil-in-water emulsion is stabilized by a surfactant having a HLB of greater than 10.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2024
From: FOLDVARI, MARIANNA
To: DDS RESEARCH INC.
Reel/Frame 066383/0906 →
Continuity (6)
Continuation
PCTCA2020051275
· Sep 23, 2020
Provisional Application
62904606
· Sep 23, 2019
Provisional Application
62904584
· Sep 23, 2019
References Cited (214)
US 4372977A
· Lover et al.
· 1983
[cited by applicant]
US 4855090A
· Wallach
· 1989
[cited by applicant]
US 4968450A
· Kamegai et al.
· 1990
[cited by applicant]
US 5804216A
· Terren et al.
· 1998
[cited by applicant]
US 5846514A
· Foster et al.
· 1998
[cited by applicant]
US 5853755A
· Foldvari
· 1998
[cited by examiner]
US 5993851A
· Foldvari
· 1999
[cited by applicant]
US 5993852A
· Foldvari et al.
· 1999
[cited by applicant]
US 6334997B1
· Foster et al.
· 2002
[cited by applicant]
US 6656499B1
· Foldvari et al.
· 2003
[cited by applicant]
US 6696424B1
· Wheeler
· 2004
[cited by applicant]
US 20030119774A1
· Foldvari et al.
· 2003
[cited by applicant]
US 20040219232A1
· Lipton
· 2004
[cited by applicant]
US 20060040354A1
· O'Keefe
· 2006
[cited by applicant]
US 20080008747A1
· Royds
· 2008
[cited by applicant]
US 20080119433A1
· Tabor
· 2008
[cited by applicant]
US 20090081142A1
· Omura et al.
· 2009
[cited by applicant]
US 20090098171A1
· Alard
· 2009
[cited by examiner]
US 20090297592A1
· Sakuraba et al.
· 2009
[cited by applicant]
US 20100166689A1
· Waugh
· 2010
[cited by applicant]
US 20110268812A1
· Cauchard et al.
· 2011
[cited by applicant]
US 20130224283A1
· Foldvari et al.
· 2013
[cited by applicant]
US 20160151283A1
· Manca et al.
· 2016
[cited by applicant]
US 20170304232A1
· Khan et al.
· 2017
[cited by applicant]
US 20180360757A1
· Doroudian et al.
· 2018
[cited by applicant]
US 20230143474A1
· Foldvari
· 2023
[cited by applicant]
US 20230157954A1
· Foldvari
· 2023
[cited by applicant]
US 20230270635A1
· Love et al.
· 2023
[cited by applicant]
US 20240122823A1
· Foldvari
· 2024
[cited by applicant]
US 20240139089A1
· Love et al.
· 2024
[cited by applicant]
US 20240189231A1
· Foldvari
· 2024
[cited by applicant]
US 20250026787A1
· Love
· 2025
[cited by applicant]
CA 2168260C
· 2000
[cited by applicant]
CA 2324403A1
· 2000
[cited by applicant]
CA 2458443A1
· 2003
[cited by applicant]
CA 3155131A1
· 2021
[cited by applicant]
CN 108778244A
· 2018
[cited by applicant]
CN 108948151A
· 2018
[cited by applicant]
EP 0711148A1
· 1996
[cited by applicant]
EP 2498792A1
· 2012
[cited by applicant]
FR 2816577A1
· 2002
[cited by applicant]
FR 2846238A1
· 2004
[cited by applicant]
FR 2876577A1
· 2006
[cited by applicant]
JP 2001514212A
· 2001
[cited by applicant]
JP 2009515579A
· 2009
[cited by applicant]
JP 2010522698A
· 2010
[cited by applicant]
JP 2019510215A
· 2019
[cited by applicant]
KR 100748035B1
· 2007
[cited by applicant]
KR 20080088888A
· 2008
[cited by applicant]
WO WO9503787A1
· 1995
[cited by applicant]
WO WO9911247A1
· 1999
[cited by applicant]
WO WO0130808A1
· 2001
[cited by applicant]
WO WO0135998A1
· 2001
[cited by applicant]
WO WO2006012414A2
· 2006
[cited by applicant]
WO WO2006116156A2
· 2006
[cited by applicant]
WO WO2008119160A1
· 2008
[cited by applicant]
WO WO2011060083A1
· 2011
[cited by applicant]
WO WO2015023601A1
· 2015
[cited by applicant]
WO WO2018144093A2
· 2018
[cited by applicant]
WO WO2018213932A1
· 2018
[cited by applicant]
WO WO2020081583A1
· 2020
[cited by applicant]
WO WO2021056106A1
· 2021
[cited by applicant]
WO WO2021216572A1
· 2021
[cited by applicant]
WO WO2022204287A1
· 2022
[cited by applicant]
WO WO2022204305A2
· 2022
[cited by applicant]
WO WO2022204308A1
· 2022
[cited by applicant]
WO WO2022204309A1
· 2022
[cited by applicant]
WO WO2023081259A2
· 2023
[cited by applicant]
Som et al (J Pharm Bioallied Sci, 2012, vol. 4, pp. 2-9) (Year: 2012).
[cited by examiner]
Koivukangas et al (Arch Dermatol Res, 1995, vol. 287, pp. 171-175) (Year: 1995).
[cited by examiner]
Dragicevic et al (Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement, Springer, 2015, pp. 253, 255-256, 258, 259, 260, 263, 264, 265, 266, 267) (Year: 2015).
[cited by examiner]
Asakawa, Hitoshi, and Fukuma, Takeshi. The molecular-scale arrangement and mechanical strength of phospholipid/cholesterol mixed bilayers investigated by frequency modulation atomic force microscopy in liquid. Nanotechn…
[cited by applicant]
Cullis, Pieter R. et al. Chapter 1: Physical properties and functional roles of lipids in membranes. Biochemistry of Lipids, Lipoproteins and Membranes :1-33 (1996).
[cited by applicant]
EP22776572.4 European Search Report dated Feb. 13, 2025.
[cited by applicant]
EP22776587.2 European Search Report dated Feb. 18, 2025.
[cited by applicant]
EP22776585.6 Supplementary Partial Search Report mailed Jan. 24, 2025.
[cited by applicant]
Foldvari, Marianna. et al. Biphasic vesicles: a novel topical drug delivery system. Journal of biomedical nanotechnology 6(5):543-557 (2010).
[cited by applicant]
Foldvari, Marianna. et al. Gene delivery into human skin in vitro using biphasic lipid vesicles. Current Drug Delivery 3(1):89-93 (2006).
[cited by applicant]
Foldvari, Marianna et al. Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Current Drug Delivery 8(3):307-319 (2011).
[cited by applicant]
Hruby: Design of cyclic peptides with biological activities from biologically active peptides: the case of peptide modulators of melanocortin receptors. Biopolymers, John Wiley. 106(6):884-888 (2016).
[cited by applicant]
Ionov, R. et al. Interactions of lipid monolayers with the natural biopolymer hyaluronic acid. Biochimica et Biophysica Acta (BBA)—Biomembranes 1667(2):200-207 (2004).
[cited by applicant]
King, Martin J. et al. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technology and Therapeutics 4(4):479-488 (2002).
[cited by applicant]
Lacquer Plump. Product Description. CNPD. Mintel. http://www.gnpd.com XP002782678. 1-7 (2008).
[cited by applicant]
Lim, Seng Han et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Scientific Reports 8(1):1596, 1-11 (2018).
[cited by applicant]
Long et al.: Transdermal delivery of peptide and protein drugs: Strategies, advantages and disadvantages. Journal of drug delivery science and technology. 60(102007):1-16 (2020).
[cited by applicant]
Moradi, Amir. et al. In Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications. Dermatologic surgery 51(4):403-408 (2025). Published on…
[cited by applicant]
Redondo-Morata, Lorena et al. Influence of cholesterol on the phase transition of lipid bilayers: a temperature-controlled force spectroscopy study. Langmuir 28(35):12851-12860 (2012).
[cited by applicant]
Singapore Patent Application No. 11202202816P Search Report dated Mar. 21, 2025.
[cited by applicant]
Soybean Phospholipids and Formulations. Lipoid 2025; [Retrieved on Mar. 11, 2025]. Available at URL:https://lipoid.com/en/products/raw-material-sources/soybean-phospholipids-formulations/ pp. 1-3.
[cited by applicant]
Thirumoorthy et al.: Novel agouti-related-protein-based melanocortin-1 receptor antagonist. Journal of Medicinal Chemistry. American Chemical Society. US. 44(24):4114-4124 (2001).
[cited by applicant]
Uchegbu et al: Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics. 172(1-2):33-70 (1998).
[cited by applicant]
U.S. Appl. No. 17/702,608 Office Action dated Dec. 11, 2024.
[cited by applicant]
U.S. Appl. No. 17/702,608 Office Action dated Jun. 4, 2025.
[cited by applicant]
U.S. Appl. No. 18/052,490 Office Action dated Mar. 24, 2025.
[cited by applicant]
Zhang, Yongtai. et al. Co-hybridized composite nanovesicles for enhanced transdermal eugenol and cinnamaldehyde delivery and their potential efficacy in ulcerative colitis. Nanomedicine Nanotechnology Biology and Medici…
[cited by applicant]
Abdulbaqi et al.: Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine. 11:2279-2304 (2016).
[cited by applicant]
Albuquerque, Edson et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev vol. 89,1: 73-120 (2009).
[cited by applicant]
Aulton's Pharmaceutical, The Design and Manufacture of Medicines. Fourth Edition. p. 442-449 (2021).
[cited by applicant]
Badenhorst et al.: Pharmaceutical Strategies for the Topical Dermal Delivery of Peptides/Proteins for Cosmetic and Therapeutic Applications. Austin J Pharmacol. 2(6):1036-1046 (2014).
[cited by applicant]
Becker, Lillian C., Safety Assessment of PEG-Distearates as Used in Cosmetics. Cosmetic Ingredient Review :1-36 (2015).
[cited by applicant]
Benson et al.: Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci. 97(9):3591-3610 (2008).
[cited by applicant]
Berge, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
[cited by applicant]
Bos et al.: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 9(3):165-169 (2000).
[cited by applicant]
Bravo et al.: Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence. Dermatol Ther. 35(12):e15903 (2022).
[cited by applicant]
Bukhari et al.: Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 120(Pt B):1…
[cited by applicant]
Bundgard, Hans., Design of Prodrugs. Elsevier, Amsterdam:1-30 (1985).
[cited by applicant]
Chinese Patent Application No. 2020800813833 First Office Action dated Apr. 27, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/470,334, inventor Foldvari; Marianna, filed Sep. 19, 2023.
[cited by applicant]
Czekalla et al.: Noninvasive Determination of Epidermal and Stratum Corneum Thickness in vivo Using Two-Photon Microscopy and Optical Coherence Tomography: Impact of Body Area, Age, and Gender. Skin Pharmacol Physiol. 3…
[cited by applicant]
Dean, Dennis C. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. Current Pharmaceutical Design 6:1-2 (2000).
[cited by applicant]
Dekan, Zoltan et al. α-Conotoxin lml incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure. J Am Chem Soc vol. 133,40: 15866-15869 (2011).
[cited by applicant]
Demarco, Steven et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorganic & Medicinal Chemistry vol. 14,24: 83…
[cited by applicant]
Dhamecha, Dinesh et al. Drug vehicle based approaches of penetration enhancement. International Journal of Pharmacy and Pharmaceutical Sciences vol. 1,1: 24-46 (2009).
[cited by applicant]
Dragicevic, Nina., Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement. Springer :1-415 (2015).
[cited by applicant]
European Patent Application No. 4034087A1 Search Report dated Sep. 27, 2023.
[cited by applicant]
Evans, Anthony E. Synthesis of Radiolabeled Compounds. Journal of Radioanalytical and Nuclear Chemistry 64(1-2):9-32 (1981).
[cited by applicant]
Falla et al.: Cosmeceuticals and peptides. Clinics in Dermatology 27:485-494 (2009).
[cited by applicant]
Fallacara et al.: Hyaluronic Acid in the Third Millennium. Polymers (Basel). 10(7):701 (2018).
[cited by applicant]
Foldvari et al.: Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv. 8(3):307-319 (2011).
[cited by applicant]
Foldvari et al.: Gene delivery into human skin in vitro using biphasic lipid vesicles. Curr Drug Deliv.3(1):89-93 (2006).
[cited by applicant]
Foldvari et al.: Permeation enhancement by molecular organization switching (MOS): Biphasic vesicles for the cutaneous delivery of proteins. In: Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhance…
[cited by applicant]
Foldvari et al.: Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment. Current Dermatology Reports. 4(1):1-7 (2015).
[cited by applicant]
Foldvari et al.: Topical Delivery of Interferon Alpha by Biphasic Vesicles: Evidence for a Novel Nanopathway across the Stratum Corneum. Molecular Pharmaceutics. 7(3):751-762 (2010).
[cited by applicant]
Foldvari M. Biphasic vesicles: a novel topical drug delivery system. J Biomed Nanotechnol. 6(5):543-557 (2010).
[cited by applicant]
Folvari: Observations of membrane fusion in a liposome dispersion: the missing fusion intermediate? F1000 Research. 4(4):1-11 (2015).
[cited by applicant]
Griffin, William et al. “HLB” or “Hydrophilic-Lipophilic Balance” value refers to standard HLB. Official Journal of the Society of Cosmetic Chemists vol. 5,4:249-256 (1954).
[cited by applicant]
Gupta, Syamasri et al. Biocompatible microemulsions and their prospective uses in drug delivery. Journal of Pharmaceutical Sciences vol. 97,1: 22-45 (2008).
[cited by applicant]
Handbook of Pharm Excipients—Glyceryl Monostearate (sixth edition) p. 290-293 (2009).
[cited by applicant]
Higuchi, Takeru, and Valentino J. Stella. Pro-Drugs as Novel Delivery Systems, vol. 14 of the ACS Symposium Series. American Chemical Society (1975).
[cited by applicant]
Horrell et al.: Melanocortin 1 Receptor: Structure, Function, and Regulation. Frontiers in Genetics 7(95):1-16 (2016).
[cited by applicant]
Huzil et al.: Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Int…
[cited by applicant]
Iaconisi et al.: Hyaluronic Acid: A Powerful Biomolecule with Wide-Ranging Applications—A Comprehensive Review. Int J Mol Sci. 24(12)(2023).
[cited by applicant]
Jayawickreme et al.: Discovery and Structure-Function Analysis of α-Melanocyte-stimulating Hormone Antagonists. The Journal of Biological Chemistry. 269(47):29846-29854 (1994).
[cited by applicant]
Kabalka, George W. et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).
[cited by applicant]
Kalamida, Dimitra et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. The FEBS Journal vol. 274, 15: 3799-3845 (2007).
[cited by applicant]
Kim et al.: A novel dermal delivery system using natural spicules for cosmetics and therapeutics. J Cosmet Dermatol. 21(10):4754-4764 (2022).
[cited by applicant]
Kim et al. Arc-poration improves transdermal delivery of biomolecules. J Cosmet Dermatol. 23(6):2240-2248 (2024).
[cited by applicant]
King et al.: Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther. 4(4):479-488 (2002).
[cited by applicant]
Kirby, Anthony et al. Gemini surfactants: new synthetic vectors for gene transfection. Angew Chem Int Ed Engl vol. 42,13: 1448-1457 (2003).
[cited by applicant]
Knerr, Patrick et al. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem Biol vol. 6,7: 753-760 (2011).
[cited by applicant]
Koivukangas et al.: Increased collagen synthesis in psoriasis in vivo. Arch Dermatol Res. 287:171-175 (1995).
[cited by applicant]
Kyte et al.: A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 157:105-131 (1982).
[cited by applicant]
Lademann et al.: Determination of the thickness and structure of the skin barrier by in vivo laser scanning microscopy. Laser Phys Lett. 5(4):311-315 (2008).
[cited by applicant]
Lane, Majella. Skin penetration enhancers. Int J Pharm vol. 447,1-2: 12-21 (2013).
[cited by applicant]
Lee et al.: Laser-assisted nanoparticle delivery to promote skin absorption and penetration depth of retinoic acid with the aim for treating photoaging. Int J Pharm. 627:122162 (2022).
[cited by applicant]
Liatsopoulou et al.: Iontophoresis in dermal delivery: A review of applications in dermato-cosmetic and aesthetic sciences. Int J Cosmet Sci. 2023;45(2):117-132 (2023).
[cited by applicant]
Lichtenberg, Dov et al. The mechanism of detergent solubilization of lipid bilayers. Biophysical Journal vol. 105,2: 289-299 (2013).
[cited by applicant]
Lotioncrafter. Lotioncrafter.com. Sorbitan Stearate Product Info. Sep. 20, 2020. pp: 1-4 [retrieved May 18, 2022] https://webarchive.org/web/20200920113912/https://lotionlcrafter.com/products/sorbitan-stearate [entire d…
[cited by applicant]
Lv et al.: Collagen-Based Dissolving Microneedles with Flexible Pedestals: A Transdermal Delivery System for Both Anti-Aging and Skin Diseases. Adv Healthc Mater. 12(21):e2203295 (2023).
[cited by applicant]
Makino et al.: Evaluation of a Hydroquinone-free Skin Brightening Product Using in Vitro Inhibition of Melanogenesis and Clinical Reduction of Ultraviolet-induced Hyperpigmentation. Journal of Drugs in Dermatology 12:s1…
[cited by applicant]
Mcclements, David Julian. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter vol. 8,6: 1719-1729 (2012).
[cited by applicant]
Mcnulty et al.: Structures of the Agouti Signaling Protein. Journal of Molecular Biology 346:1059-1070 (2005).
[cited by applicant]
Menger,Fredric et al. Gemini Surfactants. Angew Chem Int Ed Engl vol. 39,11: 1906-1920 (2000).
[cited by applicant]
Moghadam et al.: Effect of Chemical Permeation Enhancers on Stratum Corneum Barrier Lipid Organizational Structure and Interferon Alpha Permeability. Molecular Pharmaceutics. 10:2248-2260 (2013).
[cited by applicant]
Mortazavi et al.: Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 44(2):232-248 (2022).
[cited by applicant]
Nguyen, Giang et al. Making circles: recent advance in chemical and enzymatic approaches in peptide macrocyclization. Journal of Biochemistry and Chemical Sciences vol. 1,1: 1-13 (2017).
[cited by applicant]
Nix et al.: Molecular and Functional Analysis of Human β-Defensin 3 Action at Melanocortin Receptors. Chem Biol. 20(6):784-795 (2013).
[cited by applicant]
Otto et al. Formulation effects of topical emulsions on transdermal and dermal delivery. International Journal of Cosmetic Science vol. 31,1: 1-19 (2009).
[cited by applicant]
Paliwal, Himanshu et al. Pharmaceutical Considerations Of Microemulsion As A Drug Delivery System. Journal of Drug Delivery and Therapeutics vol. 9,4-S: 661-665 (2019).
[cited by applicant]
Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol. 4(3):253-258 (2012).
[cited by applicant]
PCT/CA2020/051275 International Search Report and Written Opinion dated Dec. 21, 2020.
[cited by applicant]
PCT/US2022/021554 International Preliminary Report on Patentability dated Oct. 5, 2023.
[cited by applicant]
PCT/US2022/021554 International Search Report and Written Opinion dated Jun. 10, 2022.
[cited by applicant]
PCT/US2022/021579 International Search Report and Written Opinion dated Oct. 5, 2022.
[cited by applicant]
PCT/US2022/021579 Invitation to Pay Additional Fees dated Jul. 22, 2022.
[cited by applicant]
PCT/US2022/021585 International Preliminary Report on Patentability dated Oct. 5, 2023.
[cited by applicant]
PCT/US2022/021585 International Search Report and Written Opinion dated Jul. 7, 2022.
[cited by applicant]
PCT/US2022/048780 International Search Report and Written Opinion dated Apr. 27, 2023.
[cited by applicant]
Rahiman et al.: Novasome: A Pioneering Advancement in Vesicular Drug Delivery. International Journal of Applied Pharmaceutics. 13(1):59-64 (2021).
[cited by applicant]
Sakdiset, Pajaree, et al., Potential of Stratum Corneum Lipid Liposomes for Screening of Chemical Skin Penetration Enhancers. Chemical and Pharmaceutical Bulletin 65:776-783 (2017).
[cited by applicant]
Salwowska et al.: Physiochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. 15(4):520-526 (2016).
[cited by applicant]
Sekhon, Bhupinder Singh., Surfactants: Pharmaceutical and Medicinal Aspects. Journal of Pharmaceutical Technology 1:43-68 (2013).
[cited by applicant]
Shen et al.: Effect of Nonionic Surfactants on Percutaneous Absorption of Salicylic Acid and Sodium Salicylate in the Presence of Dimethyl Sulfoxide. Journal of Pharmaceutical Sciences. 65(12):1780-1783 (1976).
[cited by applicant]
Shin et al.: Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. International Journal of Pharmaceutics. 222(2):199-203 (2001).
[cited by applicant]
Shin et al.: Enhanced transdermal delivery of triprolidine from the ethylene-vinyl acetate matrix. European Journal of Pharmaceutics and Biopharmaceutics. 54(3):325-328 (2002).
[cited by applicant]
Som, Iti, et al., Status of Surfactants as Penetration Enhancers in Transdermal Drug Delivery. Journal of Pharmacy & Bioallied Sciences 4(1) :1-8 (2012).
[cited by applicant]
Spicer, Christopher et al. Selective chemical protein modification. Nature Communications vol. 5:4740, pp. 1-14 (2014).
[cited by applicant]
Talegaonkar, Sushama et al. Microemulsions: a novel approach to enhanced drug delivery. Recent Patents on Drug Delivery & Formulation vol. 2,3: 238-257 (2008).
[cited by applicant]
Tam, James et al. Chemical Synthesis of Circular Proteins. The Journal of Biological Chemistry vol. 287,32: 27020-27025 (2012).
[cited by applicant]
U.S. Appl. No. 17/841,924 Final Office Action dated Nov. 17, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,924 Office Action dated Aug. 1, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,924 Office Action dated Jun. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,144 Office Action dated Apr. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Final Office Action dated Sep. 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Office Action dated May 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Office Action dated May 8, 2023.
[cited by applicant]
U.S. Appl. No. 17/702,608 Office Action dated Apr. 25, 2024.
[cited by applicant]
U.S. Appl. No. 18/473,073 Office Action dated Jun. 14, 2024.
[cited by applicant]
Van Staden, Daniélle et al. Development of a Self-Emulsifying Drug Delivery System for Optimized Topical Delivery of Clofazimine. Pharmaceutics vol. 12,6: 1-24 (2020).
[cited by applicant]
Website: Emulsifying Agents in Pharmaceuticals. https://pharmaeducation.net/emulsifying-agents/ 11 pages (2023).
[cited by applicant]
Williams, Adrian et al. Penetration Enhancers. Advanced Drug Delivery Reviews vol. 64:128-137 (2012).
[cited by applicant]
Zasada, Malwina et al. The assessment of the effect of a cosmetic product brightening the skin of people with discolorations of different etiology. Journal of Cosmetic Dermatology vol. 15,4: 493-502 (2016).
[cited by applicant]
Zhou, Xingli et al. Nano-formulations For Transdermal Drug Delivery: A Review. Chinese Chemical Letters vol. 29,12: 1713-1724 (2018).
[cited by applicant]
EP22890753.1 Extended European Search Report dated Aug. 19, 2025.
[cited by applicant]